Dermata Therapeutics, Inc. (DRMA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 9, 2023, by Dermata Therapeutics, Inc., a Delaware corporation. The filing primarily serves to disclose the Company's results of operations for the quarter ended September 30, 2023, via a press release furnished as Exhibit 99.1. Additionally, the report addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text references a press release containing financial results for the quarter ended September 30, 2023, but does not explicitly state specific values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Investors must refer to the attached press release (Exhibit 99.1) for these quantitative details.
Material Changes and Corporate Events
- Change in Certifying Accountants: The Company's Audit Committee appointed Moss Adams LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Departure of Prior Auditor: Mayer Hoffman McCann P.C. (MHM) notified the Company on July 28, 2023, that it would not stand for re-appointment for the fiscal year ending December 31, 2024. MHM ceased serving as the independent auditor upon the earliest of the completion of the 2023 Form 10-K, the appointment of a new firm, or April 1, 2024.
- Consultation History: The Company confirmed no consultations occurred with Moss Adams regarding accounting principles or reportable events during the two most recent fiscal years or the interim period up to November 9, 2023.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a detailed risk assessment within the text provided. The document notes that the information regarding results of operations is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into future filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2023 financial figures, including cash position and burn rate.
- Verify the transition timeline between Mayer Hoffman McCann P.C. and Moss Adams LLP to ensure no gaps in audit coverage.
- Confirm the status of the fiscal year 2023 Form 10-K filing, as the departure of the prior auditor was contingent on its completion.
- Check for any subsequent filings regarding the appointment of Moss Adams LLP for the fiscal year ending December 31, 2024.